Pharmaceuticals

MTD Group Acquires Ypsomed’s Pen Needle and Blood Glucose Monitoring Systems

bexib
By bexib 0 Min Read

The acquisition of Ypsomed’s pen needles and glucose monitoring systems is expected to increase MTD production capacity to more than 2.5 billion units.

You Might Also Like

New gut microbiome atlas could inform better treatments for digestive diseases

Patient treatment and travel: the need for further support

Researchers combine herpes virus and cancer vaccine to treat childhood brain tumors

The Enhertz Effect: A plan to build on the success of the first masterpiece

FDA approves Filspari for adult patients with IgA nephropathy

Share This Article
Previous Article Five Questions for Carl Slavicki of BNY Treasury Services
Next Article Maker Faire Hannover: 10 years of creative activity
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Upcoming seller boom for TikTok shops
Retail & E-commerce
The countdown to the reopening of the iconic Delano Miami Beach begins
Hospitality & Tourism
Remembering Maker Faires in 2024?
Manufacturing
Top 5 Open Banking Stories of 2024
Banking